Dapoxetine Hydrochloride is a short-acting SSRI specifically developed for on-demand treatment of premature ejaculation, distinguished by its rapid absorption and elimination enabling use as needed rather than daily dosing. Simson Pharma's Dapoxetine Hydrochloride reference standard and impurities support stability-indicating method development for this urology-focused serotonergic agent.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Dapoxetine Hydrochloride Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.